Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET/CT on the clinical staging (TNM staging) of MTC.
Patients of either gender, aged ≥ 18 years and ≤80 years.
Patients with pathologic findings confirming the diagnosis of MTC
Patients with MTC recurrence
Signed written consent
Pregnant or breastfeeding female patients
Patients with claustrophobic behavior
The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent